Skip to main content

Report: Defense Department Overpaid $54 Million For EpiPens

By

It looks like taxpayers didn’t just overpay for EpiPens purchased through Medicaid. According to a new report, the Department of Defense has been paying almost full retail price for the expensive emergency allergy treatment.

This is according to a Reuters analysis of available data, which found that many of the EpiPens paid for by the DoD were purchased at retail pharmacies instead of military facilities or by mail order. That means the DoD’s deep discount on the drug did not apply.

When EpiPens were purchased at retail stores, Reuters says the DoD paid an average price that was up to three times higher than the discounted rate for buying the drug at a military facility. That wouldn’t be that much of a problem if it were only a small number of patients buying EpiPens at the higher price, but Reuters reports that nearly half of these drugs were bought at retail.

Between the drug’s soaring price hikes and the increased demand for EpiPen, DoD annual spending on the allergy treatment jumped from $9 million in 2008 to $57 million in 2015.

Reuters estimates that the DoD paid $54 million during those years for EpiPens that could have been purchased for significantly less money.

The drug’s maker, Mylan, tells Reuters that it’s talking to the Pentagon about extending the DoD’s discount to purchases made at retail pharmacies.

The DoD’s EpiPen situation appears to be different than the hundreds of millions of dollars overpaid for the drug by the Center for Medicare & Medicaid Services (CMS). That dispute involved the proper classification of EpiPen in the Medicaid rebate program.

Under that program, generic or multiple-source drugs pay a smaller rebate rate to Medicaid compared to the rebates paid for patent-protected drugs or medications with no competition. For decades, EpiPen was categorized as a multiple-source drug, meaning Mylan (and the companies that previously owned the EpiPen brand) were paying the lower rebate rate.

CMS recently concluded that the drug had been mis-categorized, meaning the government had lost out on hundreds of millions of dollars in rebates from Mylan. Almost immediately after CMS revealed this overpayment, Mylan says it agreed to a $465 million settlement with the Justice Department — a settlement the DOJ has yet to discuss publicly.

EpiPen may soon get lower-price competition, both from a generic version of the drug it plans to release on its own and from Sanofi’s Auvi-Q epinephrine injector. That drug was recalled from the market in Oct. 2015 over concerns about inaccurate dosing, but is slated to return in 2017.


by Chris Morran via Consumerist

Comments

Post a Comment

Popular posts from this blog

Chrysler Deletes Its Dating Apps, Decides To Remain Single For Now

By
They say you can’t have a healthy relationship until you’re happy with yourself. That appears to be the new mantra for Fiat Chrysler: After several attempts to woo General Motors and more recently Volkswagen , the carmaker’s top executive says he plans to ditch his lovelorn ways to concentrate on his company’s bottom line.  Bloomberg reports that CEO Sergio Marchionne has turned his focus to eliminating FCA’s debt rather than eliminating its single status. Marchionne has set a goal of erasing FCA’s debt by 2019, the same year he’s set to retire. To do that, he says the company needs to do a little work on itself. “We need to be very careful that we don’t start unrealistic dreams about consolidation as we are on our way to achieve historically important results and a debt-free position,” Marchionne told investors at the carmaker’s annual meeting in Amsterdam, as reported by Bloomberg. “We are not at a point of time to discuss any alliance.” Yes, you heard that right: The man w...
Post a Comment
Read more

Study Claims 43% Of “Wild” Salmon In Stores & Restaurants Isn’t Wild At All

By
That wild salmon entrée calling to you from the menu at dinner might not be all it’s advertised. In fact a new study released Wednesday found evidence of mislabeling in nearly half of all salmon sold in restaurants and grocery stores.  The study [ PDF ] from international environmental advocacy group, Oceana, analyzed 82 salmon samples from restaurants and grocery stores, finding that 43% of the products were mislabeled. DNA testing confirmed that 69% of the mislabeled product consisted of farmed Atlantic salmon being sold as wild-caught product. According to the report, consumers satisfying their salmon craving in restaurants are misled about 67% of the time, while those who buy their seafood in a grocery store are misled 20% of the time. “Americans might love salmon, but as our study reveals, they may be falling victim to a bait and switch,” Beth Lowell, senior campaign director at Oceana, said . “When consumers opt for wild-caught U.S. salmon, they don’t expect to get a far...
Post a Comment
Read more

Introduction to Biology (IX Biology Notes Chapter 01)

By
Science: Our universe operates under certain principles. For understanding of these principles, the experiments are done and observations are made; on the basis of which logical conclusions are drawn. Such a study is called "Science". In brief science is the knowledge based on experiments and observations. Biology: The Scientific study of living organisms is called Biology. The word biology is derived from two Greek words "bios" meaning life and "logos" meaning thought, discourse, reasoning or study. It means that all aspects of life and every type of living organism are discussed in biology. Branches of Biology: Biology is divided into following branches: Morphology The study of form and structure of living organisms is called morphology. It can be further divided into following two parts: 1. The study of external parts of living organism is called external morphology. 2. The study of internal parts of living organism is calle...
Post a Comment
Read more